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Interaction of erythropoietin RNA binding protein with erythropoietin
RNA requires an association with heat shock protein 70. Synthesis of
eiythropoietin (Epo), the glycoprotein hormone that regulates red blood
cell formation, is induced in response to low oxygen stress (hypoxia), and
is regulated at both transcriptional and post-transcriptional levels. We
have previously described an Epo RNA binding protein (ERBP) which
specificafly binds to the 3'-untranslated region of Epo mRNA and is likely
involved in the regulation of Epo mRNA stability. Since heat shock
proteins (hsps) are induced in response to a variety of stresses, including
hypoxia, we tested the possibility that hsps are involved in ERBP-Epo
RNA complex formation. When human anti-hsp7o antibody was added to
ERBP-containing human hepatoma cell (Hep3B) lysates, the ERBP-Epo
RNA complex was inhibited in an electrophoretic mobility band shift
assay. In addition, the anti-hsp7o antibody-inhibited complex could be
rescued if lysates were pretreated with purified inducible hsp70, but not
with bovine serum albumin (BSA). in vivo studies using quercetin to
inhibit hsp70 induction support the notion that hsp7o is involved in
ERBP-Epo RNA complex formation. Taken together, these findings
suggest involvement of hsp70 in ERBP-Epo mRNA complex formation,
and our model suggests a novel role for hsps in the regulation of EPO
mRNA stability.
Erythropoietin (Epo) is a glycoprotein hormone that regulates
red cell mass [1], and is primarily produced by the adult kidney [21
and by the fetal liver [3]. During hypoxia, Epo RNA levels
increase significantly (50- to 100-fold) in vivo in rat kidney [4] and
in vitro in human hepatoblastoma cells (Hep3B) [5]. Both in-
creased Epo gene transcription and alterations of mRNA stability
have been found to account for Epo mRNA accumulation [6]. We
have previously identified an RNA binding protein that binds
specifically to the 3'-untranslated region (3'-UTR) of Epo mRNA
and have termed this protein erythropoietin RNA binding protein
(ERBP) [71. ERBP is composed of a 70 and a 135 to 140 kDa
complex and is expressed in murine liver, kidney, spleen, and
brain, as well as in the human hepatoma cell line Hep3B.
Stress proteins are members of a family of proteins induced in
response to a range of stresses, such as heat shock, nutrient
deprivation, viral infection, and hypoxia. Phylogenetically distant
species of prokatyotes and eukaryotes have been documented to
have as much as 50% sequence identity within their stress proteins
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[8]. The major group of classical stress proteins have molecular
sizes of 104, 90, 70, 60, and 20 kDa [9], whereas the major
oxygen-regulated proteins have molecular sizes of 260, 150, 100,
80, and 33 kDa [10]. Since most of the stress proteins are present
in normal unstressed cells, it has been suggested that they may
serve functions in the cell that may be distinct from their
participation during stress [11, 12].
The eukaryotic 70 kDa heat shock genes encode for a family of
proteins including, hsc70, a 73 kDa cognate protein that is
constitutively expressed and is involved in the uncoating of
clathrin-coated vesicles, and inducible hsp70, a 72 kDa protein
induced exclusively under stress conditions. Another member of
this family is a 78 kDa protein induced by glucose deprivation [13,
14]. Seventy kDa heat shock proteins are known to facilitate
protein folding and intracellular translocation acting as chaperons
for a multitude of proteins. However, other roles have been
described, such as the association of hsp70 with the nuclear
oncogene p53, which is believed to contribute to the neoplastic
transformation process of certain cell types [15]. Hsp7O acts on
hsp90, another heat shock protein, to improve its binding to the
steroid hormone receptors [16]. In addition, binding of hsp7O with
proteins, such as its own heat shock factor (HSF) and the
heme-regulated protein kinase (HRI), results in inhibition of the
activity of these proteins that await the right conditions for release
from hsp7o and subsequent activation [12, 17, 18].
Because one of the components of ERBP is a 70 kDa protein
and the activities of ERBP and heat shock protein expression are
affected by hypoxia, we tested the hypothesis that hsp70 is part of
the ERBP complex. Using an electrophoretic mobility shift assay
(EMSA), we found that antibodies to human inducible hsp70
inhibited complex formation. The complex could be rescued if
homogeneous inducible hsp70 was added to the antibody-treated
lysates. Surprisingly, in vivo inhibition of hsp7fi by quercetin
resulted in greater ERBP-Epo RNA complex formation. As
described in our model, it is hypothesized that hsp7O serves to
prime and sequester ERBP from Epo mRNA under normal
physiologic conditions. During hypoxia, hsp70 releases ERBP to
serve its protective function in the nucleus, thereby freeing ERBP
to bind and stabilize Epo mRNA. The results presented here
identify a new function of hsp70 and suggest that hsp7O is involved
in hematopolesis during hypoxia.
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Methods
Cell culture
Hep3B cells obtained from ATCC (Rockville, MD, USA) were
routinely cultured in Eagle's minimal essential medium (MEM)
supplemented with 10% fetal bovine serum (FBS), 0.1 mM
nonessential amino acids, 1 m sodium pyruvate, 100 U/ml
penicillin G, and 100 j.g/ml streptomycin in a humidified atmo-
sphere of 21% 02/5% C02/74% N2 at 37°C. Hypoxic conditions
were obtained by placing cells in a hypoxic chamber (Billups-
Rothenburg, Del Mar, CA, USA) (1% 02/5% C02/94% N2) for a
determined length of time. Quercetin (10 to 50 Sigma
Chemical Co., St. Louis, MO, USA) was added 4 to 16 hours prior
to hypoxic treatment as indicated in the text.
Preparation of lysates
Cells were washed after trypsinization (0.05% tlypsin and 0.53
mM EDTA; GIBCO BRL, Gaithersburg, MD, UsA) and centri-
fuged for two minutes at 500 rpm and washed twice with PBS (2.7
mM KCI, 1.2mM KH2PO4, 138.0 mi NaCI, 8.1 mivi Na2HPO4, 7%
H20 without Ca2 or Mg2). Following the second wash, the cells
were gently resuspended in PBS and counted. Hep3B cells were
transferred to an Eppendorf tube, and the cells were pelleted at
1000 X g for 5 to 10 seconds, PBS removed, and 25 mivi Tris (pH
7.9), 0.1 m'vi EDTA was added so that the final concentration was
about 2.0 >< i0 cells/i.tl. Cells were frozen and thawed through
repetitive cycles [7]. The protein concentration of each lysate was
determined using the Bradford assay (Bio-Rad).
In vitro transcription
RNA was transcribed by either SP6 or T7 RNA polymerase
from Clal-digested pSP7O containing 3'-UTR Epo cDNA [71 or
from Xhol-digested pcDNA1 containing Epo cDNA at the EcoRI
site and labeled with [32P] UTP. Specific activity was typically i0
cpm/p.g RNA.
Electrophoretic mobility shift assay
Two to 10 j.g of cytoplasmic lysate was incubated with 5 >< iO
cpm of RNA and specific or nonspecific competitor RNA in 12
mM HEPES (pH 7.9), 10% glycerol, 15 mivi KC1, 0.25 mr.i EDTA,
0.25 mrvi dithiothreitol, 5 mrvi MgCl and 200 jg/ml E. co/i transfer
RNA in a total volume of 10 1.d for 10 minutes at 30°C. Twenty
units RNase Ti were added and reaction mixtures were incubated
for an additional 15 minutes at 37°C prior to electrophoresis in a
7% native polyacrylamide gel with 0.25X TBE (Tris-borate-
EDTA) running buffer. After drying, the gel was exposed over-
night to film or to a phosphorimaging board (0.5 to 2 hr, Fuji).
Antibody or antigen (hsp70/BSA) was added 0.5 to 1 hour on ice
prior to addition of labeled probe and subsequent gel band shift
assay. Typically, 1 1.d of undiluted antibody (or as indicated) was
added for a total of 10 tl reaction mixture volume. Commercial
antibodies used are MAb hsp72 (inducible, cat. #SPA-810; Stress-
Gen Biotechnologies Corp., Victoria, Canada), MAb hsp73 (cog-
nate, cat. #MA3-014; Affinity Bioreagents Inc., Golden, CU,
USA; or StressGen, cat. #SPA-815 as indicated), and MAb PKC
(alpha, cat. #PK 10; Oxford Biomedical Research Inc., Oxford,
MI, USA).
Western blot analysis
Proteins were electrophoresed on an 8% SDS-polyacrylamide
gel and transferred to nitrocellulose for Western blot analysis [19].
Nitrocellulose membranes were incubated with human anti-induc-
ible hsp70 (at 1:500 dilution; StressGen). Immunoglobulin specif-
ically bound to hsp7o proteins were visualized by a series of
reactions using alkaline phosphatase linked goat anti-mouse IgG
(at 1:3000 dilution, BioRad), and enzyme substrate (Western
Blue, Promega). Equal loading of proteins was determined by
protein assay and confirmed by Ponceau S staining of the nitro-
cellulose blot.
Results
ERBP specifically binds to the 3'-Epo RNA
ERBP specificity for Epo RNA was determined by competition
experiments using gel mobility shift assays. Cytoplasmic lysates
from Epo-producing Hep3B cells were incubated with various
amounts of in vitro transcribed unlabeled 3'-UTR Epo RNA or
full-length GM-CSF RNA and a constant amount of radiolabeled
Epo RNA (50 to 100,000 cpm), followed by digestion with RNase
Ti. Protected Epo RNA-protein complexes were identified by
electrophoresis and autoradiography. Progressively higher con-
centrations of unlabeled Epo RNA reduced complex formation,
while unlabeled GM-CSF RNA had no effect on the specific
protein-Epo RNA complex (Fig. 1), indicating that the complex
observed is specific. The formation of this complex can also be
competitively inhibited with full-length Epo RNA (not shown)
demonstrating full-length or 3'-UTR Epo RNA may be recog-
nized by the same protein (ERBP).
Hsp7O is part of ERBP-Epo RNA complex
To determine whether hsp70 is part of the ERBP complex,
lysates from Hep3B cells were preincubated with either polyclonal
antibody to human (hu), inducible hsp70, monoclonal antibody
(MAb) to inducible hsp72, MAb to cognate hsp73, chicken
gamma globulin (Cgg), MAb protein kinase C (MAbPKC), or
reconstituted bovine hsp70 (rbhsp70). Radiolabeled Epo RNA
was then added followed by RNase digestion, electrophoresis, and
autoradiography. Samples that contained antibodies against hu-
man hsp70, hsp72, and hsp73 failed to form specific complexes,
while the sample that contained MAbPKC, Cgg, or purified
bovine hsp7O formed the specific ERBP-Epo RNA complex (Fig.
2). It should he noted that the inhibition of complex formation
observed by hsp73 pretreatment could not be duplicated with
subsequent more purified MAb batches obtained from StressGen
(cat #SPA-815). The latter batches did not cross-react with hu
inducible hsp70 on a Western blot (data not shown). Thus, it
appears that it is the inducible hsp70 involved in ERBP-Epo RNA
complex formation. Super shifting of the complex occurred when
a separate, polyclonal antibody to hu inducible hsp70 was used
(data not shown). In contrast to the other antibodies tested,
binding of this polyclonal antibody must occur at a site separate
and not essential for RNA binding.
Rescue of antibody-treated complex by hu hsp7O
Increasing amounts (0 to 35 j.g) of homogeneous hu inducible
hsp70 were added 30 minutes prior to antibody treatment (hu
monoclonal anti-inducible hsp7O, StressGen) of lysates (as de-
scribed above) and gel band shift assay. Typical results are
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approximately 60% inhibition of hsp70 of normoxic samples as
compared to untreated controls. As expected, hypoxic treatment
alone resulted in a 68% increase of inducible hsp70, as compared
with untreated controls. Quercetin and hypoxic treatment re-
sulted in an approximately 50% decrease of inducible hsp70
relative to controls. Unexpectedly, the inhibition of hsp70 resulted
in increased ERBP binding (Fig. 4B). An 80% increase for
(ng) normoxic samples and a 120% increase for hypoxic-treated sam-
ples were observed as compared with untreated controls. Care was
taken to insure that equal amounts of proteins were loaded in
each lane. Proteins were assayed by the Bradford method; then
one of two duplicate native gels was stained with Coomasie blue
(0.5%), and Western blots were stained with Ponceau S to ensure
equal loading.
Discussion
Hsp7O involvement in ERBP-Epo complex formation
Fig. 1. Inhibition of formation of the RNA -protein complex by competitor
RNA. Normoxic Hep3B cytoplasmic lysates from near confluent cultures
were prepared by freeze-thaw lysis in 25 mvi Tris (pH 7.9) and 0.5 mM
EDTA, followed by centrifugation at 15,000 >< g at 4°C for 10 minutes.
Competitor, unlabeled RNA (Epo or GM-CSF) at the amounts shown
along the top (in nanograms) was preincubated with Hep3B lysate for 10
minutes prior to addition of radiolabeled Epo RNA transcribed from
Clal-digested pSP7O EPO-3'-UTR and band-shift assay. The arrow indi-
cates the band-shifted complex. Lane 1, specific probe and lysate without
unlabeled competitor RNA; lanes 2 to 5, specific probe and lysate in the
presence of increasing amounts (as shown) of unlabeled RNA or irrele-
vant, nonspecific RNA (GM-CSF). N = 4.
depicted in the inset and corresponding graph on Figure 3.
Complex was rescued in excess when pretreated with 35 jig of
hsp70 and to 50% when pretreated with 25 jig of hsp70 as
compared to untreated control. It is possible that under the in
vitro assay conditions used, addition of large amounts of specific
protein is required to both compete off the antibody and to
stabilize complex formation. Addition of equal amounts of BSA
did not result in complex rescue (data not shown). The shifted
bands were more diffuse than for other experiments which is
attributable to prolonged incubation of the assay mixture on ice.
In vivo inhibition of hsp7O by quercetin enhances ERBP-Epo RNA
complex frrmation
Quercetin is a bioflavonoid known to inhibit hsp70 induction
[201. To assess whether in vivo hsp7O inhibition would affect
ERBP binding activity, Hep3B cells were pretreated for 16 hours
with 10 jiM quercetin before incubation in normoxic (21% 02) or
hypoxic (1% 02) conditions for an additional six hours. Inhibition
of inducible hsp70 by quercetin treatment was determined by
Western blot as described in the Methods section. Figure 4A is a
representative Western blot. Quercetin treatment resulted in an
In the experiments reported here, we have addressed the
hypothesis that hsp70 is involved in ERBP-Epo RNA complex
formation. The fact that ERBP is composed of a 70 kDa protein
and that Epo production like hsp70 is induced following hypoxia
— led to this hypothesis. Separate from its well-established "chap-
eron" role, increasing data suggest a regulatory role for hsp7O in
several important cellular processes. For example, Hutchison et al
[16] have suggested that hsp70 is required not only to prime
hsp9O, but for glucocorticoid receptor assembly. In its absence,
the receptor cannot be functionally assembled. The binding by
hsp70 to HRI prevents this kinase from inactivating initiation
factor-cs (elF-cs), a key component of an active transcriptional
machinery [18]. One-to-one binding of hsp70 to HSF may prevent
the hsp transactivating factor from trimerizing to its active form
and travelling to the nucleus, its site of activity [12, 17, 20]. Thus,
increasing evidence points to a regulatory role for hsp70.
Using a gel band shift assay, we have shown that ERBP
specifically binds to Epo RNA. The involvement of inducible
hsp70 in ERBP-Epo RNA complex formation was suggested in
gel band shift experiments pretreated with human anti-hsp70
antibodies in which complex formation was inhibited. Other
antibodies or other species-specific antibodies and antigens did
not result in complex inhibition. Additionally, the availability of
antibodies that discriminate between cognate (hsp73) and induc-
ible (hsp72) hsp70 (StressGen) allowed us to characterize induc-
ible hsp70 as the key hsp in ERBP-Epo RNA complex formation.
Further evidence for involvement of inducible hsp70 in complex
formation was seen after addition of homogeneous hu inducible
hsp70 to the antibody-treated lysates, which resulted in rescue of
the complex. By contrast, BSA addition did not rescue ERBP-Epo
RNA complex.
To eliminate concerns that the observed involvement of hsp70
in ERBP-Epo RNA complex formation was an artifact of our in
vitro conditions, quercetin, an in vivo inhibitor of hsp70, was used
to treat ERBP-containing Hep3B cells. Quercetin has been shown
to inhibit hsp7O induction by inhibiting both HSF1 accumulation
and HSFI phosphorylation [20]. Both are required steps for hsp
gene transactivation by HSF. Surprisingly, when the quercetin-
treated lysates were tested for ERBP-Epo RNA binding, it was
found that in vivo hsp7O inhibition resulted in increased ERBP-
Epo RNA complex formation. That is, there was an inverse
correlation between the amount of hsp70 and ERBP binding
C a- 
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Fig. 2. Inhibition of formation of Epo RNA-
protein complex in the presence of various agents.
Reaction mixtures were as described (Fig. 1),
except the cytoplasmic lysates (2 jsg) were
preincubated for one hour at 4°C with various
antibodies. Lane 1, control, no antibody
present; lane 2, polyclonal anti-hsp7o (hu); lane
3, 1:10 dilution of anti-hsp70 (hu); lane 4, Cgg;
lane 5, MAbPKC; lane 6, MAb hsp72
(StressGen); lane 7, MAb hsp73 (Affinity
BioReagents); lane 8, 50 ng of rbhsp70. N = 2.
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Fig. 3. Rescue of ERBP-Epo RNA complex by inducible hsp7O. Hep3B
lysates were pretreated with increasing amounts of purified inducible
hsp70 (HSP7O) for 30 minutes on ice prior to incubation on ice for an
additional hr with 1 pi anti-inducible hsp70 antibody (a-HSP7O, Stress-
Gen). Subsequently, reaction mixtures were assayed for gel band shift.
Insert is a sample autoradiogram used in data analysis. N = 3.
activity. Although the results observed for quercetin treatment are
most likely mediated through hsp 70 inhibition, we cannot rule out
the possibility that there is another mechanism by which quercetin
mediated the increased ERBP binding. Apart from hsp70 inhibi-
tion, quercetin is known to serve as an antioxidant [21]. Although
quercetin may act by both of these mechanisms to improve ERBP
binding, an hsp7O-mediated involvement is still implicated in
ERBP-Epo RNA binding given the hsp7O antibody results.
Model for ERBP activity
To explain the seemingly conflicting results, we propose the
following model (Fig. 5). Under normal physiologic conditions,
the multimeric protein ERBP is kept from binding Epo mRNA by
hsp70 sequestration. This would be analogous to a glucocorticoid,
estrogen, or progesterone receptor complex kept from binding its
consensus steroid receptor element in the absence of ligand by
hsps. Hsp7O binding may also serve to prime ERBP by exposing
disulfide bonds whose reduction has been shown to be necessary
for Epo RNA binding [22]. Interestingly, sulfhydryl reduction is
also required for hypoxia inducible factor-I (HIF-1) heterodimer-
ization [23]. HIF-1 has recently been shown to be composed of
heterodimeric proteins, one of which shares homology with the
aryl hydrocarbon receptor, itself regulated by hsp90 [24, 25].
During hypoxia, these sulfhydryl groups are reduced either
directly or mediated by an accessory protein (such as Ref-like
protein) [26]. Concomitantly, hsp70 is recruited away to the
nucleus to serve its stress function. The reduced, hsp70-free
ERBP complex is now able to bind to its target sequence on the
Epo mRNA thereby stabilizing it. We have evidence that the
ERBP binding site on Epo mRNA is a stabilizing site (unpub-
lished observations). This stabilization presumably occurs by the
physical obstruction by the bound ERBP complex of the destabi-
lizing machinery suggested to assemble downstream of the ERBP
site [27]. Studies to further prove this model are currently the
focus of our laboratory.
This association of a heat shock protein with the activity of an
RNA binding protein provides a new example of post-transcrip-
tional regulatory control.
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Fig. 5. Model for ERBP activity. Epo mRNA shown with ERBP binding
site contained within a 3' ioop. Large circle represents the ERBP protein
complex. Small shaded circles are hsp70 molecules. During normal
physiologic conditions, inducible hsp70 binds and keeps ERBP from
binding and stabilizing Epa mRNA. During hypoxia, hsp70 is sequestered
away leaving ERBP free to bind and stabilize Epo mRNA. This interac-
tion is most likely mediated by reduced sulfhydryl groups in the ERBP
complex (shown as S-S and 2-SH next to arrow).
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